Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB/ SE0000872095 /
SOBI/S
|
4/26/2024 5:24:16 PM
|
Chg.
+1.40
|
Volume |
Bid5:25:00 PM |
Ask5:25:00 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
280.60SEK
|
+0.50%
|
436,209
Turnover: 55.56 mill. |
-Bid Size: - |
-Ask Size: - |
99.57 bill.SEK |
- |
37.62 |
Fundamentals
| |
FY 2023 |
Growth (1Y) |
| Per Share |
|
| Earnings per Share: |
7.47 SEK |
-16.26% |
| EPS Diluted: |
- SEK |
-16.40% |
| Revenues per Share: |
62.43 SEK |
2.93% |
| Book Value per Share: |
95.57 SEK |
11.63% |
| Cash Flow per Share: |
12.61 SEK |
-16.23% |
| Dividend per Share: |
- SEK |
- |
| Total |
in mill. |
|
| Revenues: |
22,123.00 SEK |
17.74% |
| Net Income: |
2,409.00 SEK |
-8.68% |
| Operating Cash Flow: |
4,470.00 SEK |
- |
| Cash and Cash Equivalents: |
904.00 SEK |
- |
Valuation Ratios
| |
Current |
Latest FY* |
| P/E Ratio: |
37.62 |
35.74 |
| P/S Ratio: |
4.50 |
4.28 |
| P/BV ratio: |
2.94 |
2.79 |
| P/CF Ratio: |
22.28 |
21.17 |
| PEG: |
-2.31 |
-2.20 |
| Earnings Yield: |
2.66% |
2.80% |
| Dividend Yield: |
- |
- |
| Market Capitalization |
|
| Market Capitalization: |
99.57 bill. SEK |
94.61 bill. SEK |
| Free Float Market Cap.: |
- SEK |
- SEK |
| Market Cap. / Employee: |
56.19 mill. SEK |
53.39 mill. SEK |
| Shares Outstanding: |
354.36 mill. |
|
Profitability
| Gross Profit Margin: |
77.42% |
| EBIT Margin: |
18.38% |
| Net Profit Margin: |
10.89% |
| Return on Equity: |
7.11% |
| Return on Assets: |
3.25% |
Financial Strength
| Liquidity I / Cash Ratio: |
4.73% |
| Liquidity II / Quick Ratio: |
31.80% |
| Liquidity III / Current Ratio: |
66.36% |
| Debt / Equity Ratio: |
118.58% |
| Dynam. Debt / Equity Ratio: |
898.43% |
Efficiency
| Employees: |
1,772 |
| Personal Expenses / Employee: |
- SEK |
| Revenues / Employee: |
12,484,762.98 SEK |
| Net Income / Employee: |
1,359,480.81 SEK |
| Total Assets / Employee: |
41,775,959.37 SEK |
| * Fiscal Year End: |
12/31/2023 |
| Accounting Standard: |
IFRS |
